Verve Therapeutics, Inc. (VERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
VERV Stock Price Chart Interactive Chart >
VERV Price/Volume Stats
|Current price||$14.25||52-week high||$78.00|
|Prev. close||$13.79||52-week low||$11.30|
|Day high||$14.43||Avg. volume||679,236|
|50-day MA||$19.47||Dividend yield||N/A|
|200-day MA||$38.12||Market Cap||693.42M|
Verve Therapeutics, Inc. (VERV) Company Bio
Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.
Most Popular Stories View All
VERV Latest News Stream
|Loading, please wait...|
VERV Latest Social Stream
View Full VERV Social Stream
Latest VERV News From Around the Web
Below are the latest news stories about Verve Therapeutics Inc that investors may wish to consider to help them evaluate VERV as an investment opportunity.
No summary available.
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 4:30 p.m. ET. A live webcast will be available in the investor section of the company's website at www.vervetx.com. The w
GuruFocus data shows that Sekar Kathiresan, CEO of Verve Therapeutics Inc ( NA:VERV), sold 48.693 shares on December 28, 2021.
Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
VERV Price Returns